Taris Biomedical today announced positive results from the second arm of a study of its TAR-200 system for the treatment of patients with muscle-invasive bladder cancer (MIBC).
The most recent study arm involved 10 patients treated with TAR-200 and yielded positive safety, tolerability and preliminary efficacy data, according to Lexington, Mass.-based Taris. Combined data from both study arms shows a robust antitumor response on final histopathologic analysis after radical cystectomy (removal of the bladder and surrounding pelvic organs), good tolerability, and no detectable systemic drug exposure or associated adverse events, Taris said.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!